TrialThe Lancet. Respiratory medicine2019

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Michael A Matthay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.